Angus brings 30 years of experience across government, pharmaceuticals, consulting, emerging-market delivery, international development, and entrepreneurship.

He founded Aranda because he saw that antimicrobial access could not be solved by any single discipline alone. It required government adoption, industry participation, clinical stewardship, surveillance infrastructure, financing, and on-the-ground delivery to operate as one system.

Angus has worked across each of those domains. He served as the AMR lead for Johnson & Johnson, where he focused on solutions to the antimicrobial resistance crisis, including tuberculosis. He spent 15 years with McKinsey & Company supporting multi-year government transformation programs across Africa, including work in Sierra Leone during the Ebola crisis, Kenya on industrialization, Tanzania on government transformation, and Ethiopia on education.

He has managed two startups in technology and nonprofit sectors, helped build the second-largest medical university in Tanzania, and spent five years as a senior executive with the Australian government.

That cross-disciplinary experience is central to Aranda’s model: a practical, commercially viable system for connecting antimicrobial innovation to the patients and countries that need it most.

25 years in the pharmaceutical industry, with market experience across 14 countries in Sub-Saharan Africa

Sandra has worked across multiple multinational pharmaceutical companies in roles spanning product launches, market entry, government tenders, and access strategy. Her market experience extends from South Africa through Southern and East Africa, and her portfolio expertise includes vaccines, cardiovascular, diabetes, pain, antibiotics, hormone therapies, medical devices, and malaria.

Sandra has designed and implemented commercial strategies that have improved patient access to medicines across diverse markets, including a program to expand access to novel contraceptive methods for women in South Africa.

Public Health physician with national leadership experience in AMR, tuberculosis, and pharmacovigilance.

Goaba is based in Botswana, where she provides technical leadership on antimicrobial resistance activities nationally and supports the Ministry of Health in implementing Botswana’s AMR National Action Plan through the delivery unit. She previously served as Program Manager for Botswana’s National Tuberculosis Program at the Ministry of Health, coordinating national TB/HIV strategies, introducing pharmacovigilance systems, and acting as Principal Investigator for major prevalence surveys.

Goaba has chaired the Botswana Medicines Regulatory Authority Registration Committee, serves on multiple national technical working groups, and has authored over 20 peer-reviewed publications. Her expertise lies in translating global AMR commitments into actionable national policy.

30 years in development finance, with a focus on emerging market investment across healthcare and infrastructure.

Paul is President of Multi-National Strategies and brings extensive experience securing Development Finance Institution funding for emerging market projects in healthcare, housing, real estate, and manufacturing. He designed the first debt-for-nature swap in Bolivia and has advised governments on debt restructuring with the IMF, World Bank, and Paris Club creditors.

Paul was engaged by George Soros to assist governments across Eastern Europe with external debt restructuring, privatization, and joint venture formation. For Soros Fund Management, he helped establish the first regional private equity fund backed by OPIC (now the Development Finance Corporation).

Former CEO, pharmaceutical executive, global health expert, and professor.

Jeff is the former CEO of Rabin Martin, a global health consultancy. He spent 20 years with Merck (MSD) as Vice President of External Affairs for Europe, the Middle East and Africa, served as President of the Merck Company Foundation, and was President and CEO of the Global Health Council. He is Chairman of the Corporate Council on Africa.

Jeff developed several public-private partnerships, including ACHAP in Botswana, and managed others including the Mectizan Donation Program. He has delivered over $750 million in product donations and humanitarian relief and spent over 10 years building Merck’s policy initiatives across Europe, the Middle East, Africa, Latin America, and Canada.